Sterile Systemic Inflammatory Responses Following Acute Injury: Mechanisms, Clinical Implications, and Management

Abstract

Sterile systemic inflammatory responses (SIRS) following acute injury represent a critical pathophysiological process distinct from infection-induced sepsis, yet they share overlapping clinical features and outcomes. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical manifestations, diagnostic criteria, and management strategies for SIRS in the context of acute non-infectious insults, such as trauma, burns, pancreatitis, and ischemia-reperfusion injury. Special emphasis is placed on mechanistic insights, recent advances in biomarker discovery, and guideline-based therapeutic approaches, with practical implications for critical care and multidisciplinary management. The article further addresses emerging therapies and guideline recommendations, providing a comprehensive resource for clinicians and healthcare professionals managing patients at risk for or affected by sterile SIRS.

Introduction

Sterile systemic inflammatory responses following acute injury, commonly referred to as SIRS, are a well-recognized phenomenon in critical care and trauma medicine. Unlike sepsis, which is triggered by infection, sterile SIRS arises from non-infectious insults such as trauma, major surgery, pancreatitis, burns, and ischemia-reperfusion injury. These systemic responses are mediated by endogenous danger signals released from damaged tissues, leading to widespread inflammatory activation that can progress to organ dysfunction or failure. Understanding the mechanisms, clinical presentation, diagnostic challenges, and management of sterile SIRS is essential for optimizing outcomes, minimizing iatrogenic harm, and guiding future research in critical illness. This review aims to provide a comprehensive overview of sterile SIRS, focusing on recent evidence, mechanistic understanding, and clinical translation.

Epidemiology / Disease Burden

Sterile SIRS is a frequent complication in patients with significant acute injury. Epidemiological studies indicate that up to 70% of severely injured trauma patients exhibit SIRS criteria within the first 48 hours post-injury. The incidence is similarly high among patients with severe acute pancreatitis and extensive thermal burns. Although the precise global burden is challenging to quantify due to diagnostic overlap with infection-related SIRS, sterile SIRS is associated with increased morbidity, prolonged intensive care unit (ICU) stays, and a heightened risk of developing secondary complications such as multiple organ dysfunction syndrome (MODS). Mortality rates vary, but the presence of persistent or severe SIRS correlates strongly with adverse outcomes, emphasizing the need for early recognition and targeted interventions.

Pathophysiology

The pathogenesis of sterile SIRS is driven by the release of damage-associated molecular patterns (DAMPs) from necrotic or stressed cells following acute injury. DAMPs including high-mobility group box 1 (HMGB1), heat shock proteins, mitochondrial components, and extracellular ATP activate pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) and the NOD-like receptor family (NLRs) on immune cells. This triggers the assembly of inflammasomes and the release of pro-inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α), chemokines, and acute-phase reactants. The resulting systemic inflammatory milieu leads to endothelial activation, increased vascular permeability, leukocyte recruitment, and coagulation cascade activation. While initially protective, excessive or dysregulated inflammation can cause collateral tissue damage, microvascular dysfunction, and ultimately, organ failure. Importantly, the balance between pro-inflammatory and compensatory anti-inflammatory responses determines clinical outcomes, with some patients progressing to immunosuppression and increased susceptibility to secondary infections.

Risk Factors

Several patient- and injury-specific factors modulate the risk and severity of sterile SIRS following acute injury. High-risk populations include individuals with extensive tissue trauma (e.g., polytrauma, crush injuries), major burns, severe acute pancreatitis, and those undergoing complex surgical procedures. Advanced age, preexisting comorbidities (e.g., diabetes, chronic liver disease), and genetic predispositions affecting inflammatory pathways also contribute to increased susceptibility. Additional risk factors include delayed or inadequate resuscitation, hypoperfusion, and the presence of ischemia-reperfusion injury. Understanding these risk determinants is vital for risk stratification, early identification, and tailored management strategies in the acute care setting.

Clinical Features

The clinical presentation of sterile SIRS is characterized by the classic criteria: tachycardia, tachypnea, fever or hypothermia, and leukocytosis or leukopenia. However, these features are nonspecific and overlap with infection-driven SIRS. Additional findings may include hypotension, altered mental status, oliguria, and laboratory evidence of organ dysfunction (e.g., elevated creatinine, transaminases, lactate). Importantly, sterile SIRS may precede or coexist with secondary infections, complicating the clinical picture. Persistent or escalating SIRS is a harbinger of MODS, necessitating vigilant monitoring and early intervention. Distinguishing sterile from infectious SIRS remains a critical challenge in critical care practice.

Diagnosis

Diagnosing sterile SIRS is fundamentally clinical, based on established criteria (e.g., American College of Chest Physicians/Society of Critical Care Medicine SIRS criteria) in the context of a known non-infectious insult and absence of infection. Laboratory tests may reveal elevated inflammatory markers (CRP, procalcitonin, ferritin), though these are not specific. Recent research has focused on novel biomarkers (e.g., cell-free DNA, mitochondrial DAMPs, plasma HMGB1) to aid in distinguishing sterile from infectious SIRS, but their clinical utility remains under investigation. Imaging and microbiological studies are essential to exclude occult infection. A multidisciplinary approach, integrating clinical judgment with serial assessments and laboratory data, is paramount for accurate diagnosis and management.

Treatment & Management

Management of sterile SIRS centers on prompt recognition, supportive care, and mitigation of the underlying injury. Early goal-directed resuscitation, optimization of oxygen delivery, vigilant hemodynamic monitoring, and organ support (e.g., mechanical ventilation, renal replacement therapy) are cornerstones of care. Avoidance of unnecessary antibiotics is crucial to reduce antimicrobial resistance and adverse effects. Adjunctive strategies, such as temperature control, glucose management, and thromboprophylaxis, contribute to improved outcomes. In cases of severe sterile SIRS, immunomodulatory therapies (e.g., corticosteroids, biologics targeting specific cytokines) have been explored, but routine use is not recommended outside clinical trials due to inconsistent efficacy and safety concerns. Close collaboration among trauma, surgical, and critical care teams is essential for comprehensive management.

Recent Advances / Emerging Therapies

Recent advances in the understanding of sterile SIRS have propelled the development of biomarker-guided diagnostic algorithms and targeted immunotherapies. Proteomic and transcriptomic profiling holds promise for early risk stratification and personalized management. Monoclonal antibodies targeting DAMPs (such as HMGB1 inhibitors), inflammasome inhibitors, and agents modulating PRR signaling are under investigation in preclinical and early clinical studies. Mesenchymal stem cell therapy is an emerging modality with immunomodulatory and tissue-reparative properties, showing potential in animal models and early-phase trials. Nevertheless, translating these innovations into routine clinical care requires robust evidence from large-scale randomized controlled trials.

Guideline Recommendations

Current guidelines emphasize the importance of early recognition and supportive management of SIRS, regardless of etiology. The Surviving Sepsis Campaign and critical care societies highlight the need for careful differentiation between sterile and infectious SIRS to guide antibiotic stewardship. Routine use of immunomodulatory agents is not recommended outside research settings. Multidisciplinary team involvement, continuous monitoring, and individualized care plans are strongly endorsed. Ongoing research and the integration of new biomarkers and therapies into evidence-based guidelines will be pivotal in improving patient outcomes.

Conclusion

Sterile SIRS following acute injury is a complex, multifaceted syndrome with significant clinical implications. Advances in mechanistic understanding, biomarker discovery, and supportive care strategies have improved recognition and management, yet challenges remain in diagnosis and targeted therapy. Future research should focus on personalized approaches, validated biomarkers, and novel immunomodulators to mitigate the burden of sterile SIRS. Clinicians must maintain a high index of suspicion, employ evidence-based interventions, and collaborate across disciplines to optimize outcomes for this vulnerable patient population.